Buffalo Translational Consortium News

Home-Brewed Drugs and the Drug Development Process

Posted on 06/06/17 at 08:53 am

 

Presented by the UB Clinical and Translational Science Institute Drug Development Core

  • Case studies in drug discovery and pre-clinical development
  • Opportunities to become familiar with GLP and pre-clinical drug development programs
  • Regulatory compliance leading to IND application
  • Strategies for translation to Phase I study design

Who: UB CTSI Investigators with drug discovery and drug development research programs

Where: Roswell Park Cancer Institute, Zebro Conference Room

When: Monthly, 4 – 5 p.m., first Tuesday of each month (except July, second Tuesday)

Schedule:

Date

Presenter(s)

Topic

6/6/17

Andrei Gudkov, PhD, DSc

NAMPT Inhibitor OT-82 targeting energy metabolism in hematologic malignancies

7/11/17

Katerina Gurova, MD, PhD

Joseph Skitzki, MD

Curaxins – Novel epigenetic anticancer drug

8/1/17

Ravindra Pandey, PhD

Sandra Gollnick, PhD

New drug development perspectives in PDT

9/5/17

Lyudmila Burdelya, PhD

Vadim Krivokrysenko. PhD

Entolimod as a dual use oncology biodefense drug

10/3/17

Robert Fenstermaker, MD

Anti-GBM vaccine

CTSI Pilot Study awardee working on battery-free pacemaker

Posted on 05/24/17 at 07:54 am

Like conventional pacemakers, tiny new leadless pacemakers are designed to work for about 12 years.

But because these devices are placed inside the heart — as opposed to a cavity in the chest — tissue grows around them. As a result, retrieving these devices for a battery replacement might not always be possible. Instead, doctors may allow old pacemakers to pile up inside the heart while inserting new devices as needed.

There is no known danger associated with this practice, but Hooman Ansari, a PhD candidate at the University at Buffalo’s School of Engineering and Applied Sciences, is working on a tidy solution.

Working under the supervision of M. Amin Karami, assistant professor in UB’s Department of Mechanical and Aerospace Engineering and director of the Intelligent Dynamic Energy and Sensing Systems Lab (IDEAS Lab), Ansari and colleagues are developing a piezoelectric system that converts the heart’s vibrational energy into electricity to power pacemakers.

Read more here.

Ansari was the recipient of a CTSI Pilot Studies Program award in the 2015-16 cycle of funding.

Putting surgeons, researchers together is leading to world-class innovations

Posted on 05/19/17 at 03:30 pm
Putting surgeons and researchers together in the same facility is leading to world-class innovations.

L. Nelson “Nick” Hopkins is a pioneer in the use of catheters — long, flexible tubes — inserted into the vascular system in the groin and threaded to the brain to treat strokes. The procedure, once called “crazy” by the medical establishment, is now the preferred method in many situations.

His early use of endovascular surgery led Hopkins, SUNY Distinguished Professor in the Department of Neurosurgery, and a neurosurgeon with UB Neurosurgery, to confer with other types of surgeons — cardiologists, vascular surgeons and radiologists — who were using the technique. The cross-referencing broadened Hopkins’ appreciation for coming at a problem from different angles.

That cooperative approach is the driving force behind numerous research efforts now underway at a facility on the burgeoning Buffalo Niagara Medical Campus. The building is a partnership between UB and Kaleida Health that Hopkins helped usher into existence. The 10-story building houses Kaleida’s Gates Vascular Institute, dedicated to patient care, of which Hopkins is president, and UB’s Clinical and Translational Research Center (CTRC), dedicated to translational research. The juxtaposition allows for an unprecedented level of collaboration among clinical researchers, translational scientists, surgeons and engineers.  

Researchers in UB’s CTRC study problems across the entire translational spectrum, from biomarkers for sudden cardiac death and the genetic architecture of Alzheimer’s disease to depression-related asthma and new treatments for macular degeneration.

Read more here.

Dubocovich honored with President’s Medal

Posted on 05/18/17 at 07:46 am

Margarita L. Dubocovich, PhD, SUNY Distinguished Professor of pharmacology and toxicology has been awarded the UB President’s Medal, which recognizes “truly extraordinary effort on behalf the university and the communities we serve,” according to University at Buffalo President Satish K. Tripathi, PhD.

Tripathi presented the award during the Jacobs School of Medicine and Biomedical Sciences commencement ceremony on April 28.

“Dr. Dubocovich has had a broad and profound impact in her field of study, as well as her academic community at the University at Buffalo, as a scholar, teacher, mentor and administrator,” Tripathi said, adding that her work “truly embodies the excellence of our faculty and the university.”

Dubocovich is considered the world’s foremost authority on melatonin research and the regulation of the hormone’s receptors in the brain and body. She is credited with discovering the functional role of melatonin receptor types that have revolutionized the field;  her research has significantly broadened the scientific understanding of melatonin and its effect on circadian rhythms, sleep disorders and depression.

Page 2 of 30